Baird analyst Brian Skorney reiterated an Outperform rating and $23 price target on Sarepta Therapeutic (NASDAQ: SRPT), saying the FDA's request for dystrophin analysis is a positive for SRPT shares.

"We believe it signals a clear indication that the agency is willing to grant eteplirsen ‎accelerated approval, provided the expression of dystrophin in the biopsied samples from the PROMOVI study is consistent with the results of Study 201/202," Skorney said.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $16.05 yesterday.

Analyst Comments FDA

Piper Jaffray Remains Negative on Sarepta (SRPT), 'Unable to Handicap Chances for AA'June 7, 2016 9:08 AM Jefferies Continues to See Low Probablity of Sarepta (SRPT) ApprovalJune 7, 2016 7:50 AM Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - OppenheimerJune 7, 2016 6:49 AM Wedbush Upgrades Sarepta Therapeutic (SRPT) to Outperform, $36 PTJune 7, 2016 6:40 AM Amid Dystrophin Data Request, Uncertainty Remains in Sarepta (SRPT) - LeerinkJune 7, 2016 6:16 AM Sarepta Therapeutics (SRPT) Surges as FDA Requests Dystrophin Data for eteplirsen NDAJune 6, 2016 5:45 PM Sarepta Therapeutics (SRPT) Says FDA Requests Dystrophin DataJune 6, 2016 5:41 PM